References
- Dorris P. A. Endogenous inhibitors of the Na, K pump. Miner Electrolyte Metab. 1996; 22: 303–310
- Komiyama Y., Mori T., Okuda K., Munakata M., Murakami T., Masuda M., Goto A., Yamada K., Takahashi H. Effects of intracerebroventricular administration of 6-hydroxydopamine on ouabain-like immunoreactivity in plasma and the hypothalamo-pituitary axis in rats. J Hypertens. 1996; 14: 447–452
- Komiyama Y., Kumura Y., Nishimura N., Hara K., Mori T., Okuda K., Munakata M., Masuda M., Murakami T., Takahashi H. Vasodepressor effects of exercise are accompanied by reduced circulating ouabainlike immunoreactivity and the normalization of nitric oxide synthesis. Clin Exp Hypertens 1997; 19: 363–372
- Miller J. J., Valdes R., Jr. Approaches to minimizing interference by cross-reacting molecules in immunoassay. Clin Chem. 1991; 37: 144–153
- Lichtstein D., Gati I., Ovadia H. Bufalin binding protein. J Cardiovasc Res 1993; 22: S102–S105
- Antrovic R., Linder D., Hahnen J., Schoner W. Affinity labeling of a sulfhydryl group in the cardiac glycoside receptor site of Na+/K+-ATPase by N-hydroxysuccinimidyl derivatives of digoxigenin. Eur J Biochem. 1995; 227: 61–67
- Antrovic R., Sich B., Kirch U., Schneider R., Eim C., Li S.-Q., Ahlemeyer B., Tepel M., Zidek W., Schoner W. Endogenous “digitalis”: Proscillaridin A immunoreactivity, an other compound of a group of endogenous “cardiac glycoside”? —The digitalis receptor, its endogenous ligand and a transport globulin in plasma—. Therapeutic Res. 1996; 17: 146–157
- Westphal U., Burton R. M., Harding G. B. Characterization of Steroid-binding glycoproteins: Methodological comments. Method Enzymol. 1975; 34: 91–104
- Connell G. E., Painter R. H. Fragmentation of immunoglobulin during storage. Can J Biochem. 1966; 44: 371–379
- Page M., Ling C., Bentley M., Forsey T., Longstaff C., Thorpe R. Fragmentation of therapeutic human immunoglobulin preparations. Vox Sang. 1995; 69: 183–194
- Zhang L., Nakaya K., Yoshida T., Kuraiwa Y. Induction of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res. 1992; 52: 4634–4641
- Jing Y., Ohizumi H., Kawazoe N., Hashimoto S., Masuda Y., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro:Association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res. 1994; 85: 645–651
- Watabe M., Masuda Y., Nakajo S., Yoshida T., Kuroiwa Y., Nakaya K. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem. 1996; 271: 14067–14073
- Numazawa S., Inoue N., Nakura H., Sugiyama T., Fujino E., Shinoki M., Yoshida T., Kuroiwa Y. A cardiotonic steroid bufalin-induced differentiation of THP-1 cells. Involvement of Na+, K+-ATPase inhibition in the early changes in proto-oncogene expression. Biochem Pharmacol. 1996; 52: 321–329
- Falcone D. J., Borth W., McCaffrey T. A., Mathew J., McAdam K. Regulation of macrophage receptor-bound plasmin by autoproteolysis. J Biol Chem. 1994; 269: 32660–32666
- Loscalzo J. The macrophage and fibrinolysis Semin Thromb Hemost. 1996; 22: 503–506